What’s around the corner? Take a peek at 4 technologies in progress aimed at improving diabetes management.

The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?

Metabolic issues are a large part of type 2 diabetes (T2DM) and particularly lipid disorders.

GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.

Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.

Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.

What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?


Subscribe to Diabetes on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.